Skip to main content
Fig. 6 | Experimental Hematology & Oncology

Fig. 6

From: A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy

Fig. 6

Safety profile of CD22/CD19 CAR-T therapy. a Temperature change and occurrence of fever of each patient after CD22/CD19 CAR-T cells infusion. b, c C-reactive protein (b) and ferritin (c) in circulating peripheral blood of each patient at different time points. d–g Change of cytokine levels, including IFN-γ, IL-2R, TNF-α, IL-6, and IL-10 in 4 patients after received sequential CAR-T therapy. Fold change of cytokines was calculated via the formula: Fold change of cytokines = cytokine levels at different times/cytokine levels on day -2 or day 0 before CAR-T cells infusion

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us